Trials / Completed
CompletedNCT01120457
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of BMS-936564 (MDX-1338) in relapsed Acute myelogenous leukemia (AML) and other selected B-cell cancers and to determine the maximum tolerated dose (MTD) of the drug alone in relapsed/refractory AML
Conditions
- Acute Myelogenous Leukemia
- Diffuse Large B-Cell Leukemia
- Chronic Lymphocytic Leukemia
- Follicular Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-936564 (Anti-CXCR4) |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2010-05-11
- Last updated
- 2015-03-06
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01120457. Inclusion in this directory is not an endorsement.